… tumors have been known as NFPAs, but specialists increasingly prefer the term silent pituitary
tumor (SPT) [2] to define pituitary tumors … but do not secrete clinically relevant hormones [2, …

… Although some cases of SGHA have been shown to develop features of acromegaly during
the follow-up period [19, 26], we did not observe progression to acromegaly after surgery. …

… approach, including clinical and neuroimaging features, immunohistochemistry for hormones
and … Silent PTs (SPTs) can be clinically silent or totally silent depending on whether or not, …

… Pathological analysis of NFPA tissue enables NFPAs to be divided into silent pituitary
adenomas (SPAs) versus null-cell adenomas (… SPAs are adenomas with evidence of hormone or …

… to analyse the clinical and pathological features of different types of pituitary adenomas (PAs…
However, ~80% of clinically non-functioning or silent pituitary tumours are of the …

… clinical and pathological features of high-risk pituitary … Silent corticotroph adenoma may
transform into carcinoma, as described previously [59]. These clinical and pathological features …

… only considered in case of residual tumor growth or relapse, due to its potential side effects.
… A silent corticotroph adenoma can be completely silent, but sometimes also revealed …

… with a final histopathological diagnosis of pituitary adenoma were included in our study. … In
the largest series of SCAs to date, we compared the clinical features of SCAs and SGAs under …

… Our findings suggest that SCAs are relatively aggressive pituitary adenomas with a higher
propensity for tumor progression. These data corroborate findings from prior studies, lending …

… Organization classification of endocrine tumors defines pituitary adenomas based on their …
of silent corticotroph adenomas (SCAs). Unlike functioning corticotroph adenomas in patients …